Роль маркеров фиброза в стратификации риска фибрилляции предсердий у пациентов с метаболическим синдромом
https://doi.org/10.18705/2311-4495-2016-3-3-17-25
Аннотация
Об авторах
Валерий Александрович ИонинРоссия
Елена Ивановна Баранова
Россия
Список литературы
1. Savelieva I., Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31(2): 55-62.
2. Chamberlain A.M., Agarwal S.K., Ambrose M., et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010; 159(5): 159-164.
3. De Boer R.A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1): 60-68.
4. Jennifer E.H. et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-734.
5. Nattel S., Burstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1(1): 62-73.
6. Menezes A.R., Lavie C.J., Di Nicolantonio J.J. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013; 88(4): 394-409.
7. Akoum N., Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep. 2014; 16(8): 518.
8. Beinart R. et al. Сardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013; 10(9): 1325-1331.
9. Weber K.T. et al. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets. 2003; 4(6): 505-516.
10. Yen-Hung L. et al. Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One. 2014; 9(9): e95254.
11. Yalcin M.U. et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015; 26(6): 635-640.
Рецензия
Для цитирования:
Ионин В.А., Баранова Е.И. Роль маркеров фиброза в стратификации риска фибрилляции предсердий у пациентов с метаболическим синдромом. Трансляционная медицина. 2016;3(3):17-25. https://doi.org/10.18705/2311-4495-2016-3-3-17-25
For citation:
Ionin V.A., Baranova E.I. The role of fibrotic markers in risk stratification of atrial fibrillation in patients with metabolic syndrome. Translational Medicine. 2016;3(3):17-25. (In Russ.) https://doi.org/10.18705/2311-4495-2016-3-3-17-25